NO984093L - FremgangsmÕter for lindring av neuropatisk smerte ved bruk av prosaposinavledede peptider - Google Patents

FremgangsmÕter for lindring av neuropatisk smerte ved bruk av prosaposinavledede peptider

Info

Publication number
NO984093L
NO984093L NO984093A NO984093A NO984093L NO 984093 L NO984093 L NO 984093L NO 984093 A NO984093 A NO 984093A NO 984093 A NO984093 A NO 984093A NO 984093 L NO984093 L NO 984093L
Authority
NO
Norway
Prior art keywords
prosaposin
neuropathic pain
methods
derived peptides
relieving neuropathic
Prior art date
Application number
NO984093A
Other languages
English (en)
Norwegian (no)
Other versions
NO984093D0 (no
Inventor
John S O'brien
Original Assignee
Univ California
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ California filed Critical Univ California
Publication of NO984093D0 publication Critical patent/NO984093D0/no
Publication of NO984093L publication Critical patent/NO984093L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0618—Cells of the nervous system
    • C12N5/0619—Neurons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • General Health & Medical Sciences (AREA)
  • Neurosurgery (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Toxicology (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
NO984093A 1996-03-05 1998-09-04 FremgangsmÕter for lindring av neuropatisk smerte ved bruk av prosaposinavledede peptider NO984093L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/611,307 US6271196B1 (en) 1996-03-05 1996-03-05 Methods of alleviating neuropathic pain using prosaposin-derived peptides
PCT/US1997/004143 WO1997032895A1 (en) 1996-03-05 1997-03-05 Methods of alleviating neuropathic pain using prosaposin-derived peptides

Publications (2)

Publication Number Publication Date
NO984093D0 NO984093D0 (no) 1998-09-04
NO984093L true NO984093L (no) 1998-11-04

Family

ID=24448513

Family Applications (1)

Application Number Title Priority Date Filing Date
NO984093A NO984093L (no) 1996-03-05 1998-09-04 FremgangsmÕter for lindring av neuropatisk smerte ved bruk av prosaposinavledede peptider

Country Status (16)

Country Link
US (2) US6271196B1 (cg-RX-API-DMAC10.html)
EP (1) EP0929569B1 (cg-RX-API-DMAC10.html)
JP (1) JP4138006B2 (cg-RX-API-DMAC10.html)
KR (1) KR100507715B1 (cg-RX-API-DMAC10.html)
AT (1) ATE340187T1 (cg-RX-API-DMAC10.html)
AU (1) AU734566B2 (cg-RX-API-DMAC10.html)
CA (1) CA2248139C (cg-RX-API-DMAC10.html)
CZ (1) CZ297384B6 (cg-RX-API-DMAC10.html)
DE (1) DE69736712T2 (cg-RX-API-DMAC10.html)
IL (1) IL126082A0 (cg-RX-API-DMAC10.html)
NO (1) NO984093L (cg-RX-API-DMAC10.html)
NZ (1) NZ331757A (cg-RX-API-DMAC10.html)
PL (1) PL187917B1 (cg-RX-API-DMAC10.html)
RU (2) RU2266129C2 (cg-RX-API-DMAC10.html)
SK (1) SK122898A3 (cg-RX-API-DMAC10.html)
WO (1) WO1997032895A1 (cg-RX-API-DMAC10.html)

Families Citing this family (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5571787A (en) * 1993-07-30 1996-11-05 Myelos Corporation Prosaposin as a neurotrophic factor
US6849602B1 (en) * 1996-03-05 2005-02-01 The Regents Of The University Of California Compositions for alleviating neuropathic pain with prosaposin receptor agonists
AU4267297A (en) * 1997-09-11 1998-09-22 Regents Of The University Of California, The Method of alleviating neuropathic pain
CA2282827A1 (en) * 1997-03-05 1998-09-11 The Regents Of The University Of California Method of alleviating neuropathic pain
AU7795698A (en) * 1997-03-24 1998-10-20 Myelos Corporation Synthetic saposin c-derived neurotrophic peptides
US6458357B1 (en) * 1997-09-09 2002-10-01 Myelos Corporation Retro-inverso neurotrophic and analgesic peptides
AU9774698A (en) * 1997-09-09 1999-03-29 Regents Of The University Of California, The Inhibition of apoptotis using prosaposin receptor agonists
BR9913490A (pt) * 1998-08-28 2001-09-25 Myelos Corp Prosaposina cìclicos e seus usos
US20020028783A1 (en) * 1999-09-09 2002-03-07 O'brien John S. Method of stimulating prosaposin receptor activity
USRE45976E1 (en) * 1999-02-24 2016-04-19 Tact Ip, Llc Methods of inhibiting the action of TNF for neurological conditions by administering etanercept intrathecally
AU4328500A (en) * 1999-03-30 2000-10-16 Myelos Corporation Retro-inverso prosaposin-derived peptides and use thereof
US7309687B1 (en) 1999-04-13 2007-12-18 The Kenneth S. Warren Institute, Inc. Methods for treatment and prevention of neuromuscular and muscular conditions by peripherally administered erythropoietin
US7345019B1 (en) 1999-04-13 2008-03-18 The Kenneth S. Warren Institute, Inc. Modulation of excitable tissue function by peripherally administered erythropoietin
WO2000077029A1 (en) * 1999-06-16 2000-12-21 Myelos Corporation Retro-inverso peptides derived from leukemia inhibitory factor
US7109168B1 (en) 2000-06-16 2006-09-19 Myelos Corporation Retro-inverso peptides derived from leukemia inhibitory factor
WO2000077028A1 (en) * 1999-06-16 2000-12-21 Myelos Corporation Retro-inverso peptides derived from interleukin-3
EP1183267A4 (en) * 1999-06-16 2002-09-18 Myelos Corp INTERLEUKIN D RIV S PEPTIDES R TRO-INVERSES
US7135461B1 (en) 2000-06-16 2006-11-14 Myelos Corporation Retro-inverso peptides derived from interleukin-6
US20050074747A1 (en) * 2000-09-08 2005-04-07 Wadih Arap Biopanning and rapid analysis of selective interactive ligands (brasil)
US7420030B2 (en) 2000-09-08 2008-09-02 The Board Of Regents Of The University Of Texas System Aminopeptidase A (APA) targeting peptides for the treatment of cancer
US20040170955A1 (en) 2000-09-08 2004-09-02 Wadih Arap Human and mouse targeting peptides identified by phage display
US7452964B2 (en) * 2001-09-07 2008-11-18 Board Of Regents, The University Of Texas System Compositions and methods of use of targeting peptides against placenta and adipose tissues
US6531121B2 (en) 2000-12-29 2003-03-11 The Kenneth S. Warren Institute, Inc. Protection and enhancement of erythropoietin-responsive cells, tissues and organs
US20060287240A1 (en) * 2001-03-09 2006-12-21 O'brien John S Method of stimulating prosaposin receptor activity
US20040176290A1 (en) * 2001-07-18 2004-09-09 Renata Pasqualini Anti-angiogenic state in mice and humans with retinal photorecptor cell degeneration
US20040048243A1 (en) * 2001-09-07 2004-03-11 Wadih Arap Methods and compositions for in vitro targeting
US8507445B2 (en) * 2001-09-07 2013-08-13 Board Of Regents, The University Of Texas System Compositions and methods of use of targeting peptides for diagnosis and therapy of human cancer
US7671010B2 (en) * 2002-08-30 2010-03-02 The Board Of Regents Of The University Of Texas System Compositions and methods of use of targeting peptides for diagnosis and therapy of human cancer
WO2004016167A1 (en) * 2002-08-16 2004-02-26 The General Hospital Corporation Non-invasive functional imaging of peripheral nervous system activation in humans and animals
US7166691B2 (en) * 2002-12-20 2007-01-23 Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College Saposin C and receptors as targets for treatment of benign and malignant disorders
WO2004084930A1 (en) * 2003-03-26 2004-10-07 Develogen Aktiengesellschaft Use of saposin-related proteins for preventing and treating obesity, diabetes and/or metabolic syndrome
RU2358735C2 (ru) * 2003-03-28 2009-06-20 Акадиа Фармасьютикалз Инк. Агонисты м1 мускариновых рецепторов для противоболевой терапии
CN100366286C (zh) * 2003-04-28 2008-02-06 常州南云科技有限公司 Saposin C-DOPS:一种抗癌新药
US7834147B2 (en) * 2003-04-28 2010-11-16 Childrens Hospital Medical Center Saposin C-DOPS: a novel anti-tumor agent
US9345745B2 (en) * 2005-04-29 2016-05-24 Bo Wang Methods for treating inflammatory disorders and traumatic brain injury using stabilized non-hematopoietic EPO short peptides
EP1736481A1 (en) * 2005-05-13 2006-12-27 Charite Universitätsmedizin-Berlin Erythropoietin variants
RU2317829C2 (ru) * 2005-10-05 2008-02-27 Федеральное государственное учреждение науки "Екатеринбургский медицинский научный центр профилактики и охраны здоровья рабочих промпредприятий" Федеральной службы по надзору в сфере защиты прав потребителей и благополучия человека Способ лечения мононевропатий верхних конечностей
US7964585B2 (en) * 2006-03-14 2011-06-21 Case Western Reserve University Composition and method of treating peripheral neuropathy
RU2345786C2 (ru) * 2007-02-27 2009-02-10 Андрей Евгеньевич Кульчиков Способ лечения непрерывно-прогредиентных дегенеративных и демиелинизирующих заболеваний
KR20190085187A (ko) 2008-01-22 2019-07-17 아라임 파마슈티칼즈, 인크. 조직 손상 관련 질환 및 장애를 예방 및 치료하기 위한 조직 보호 펩티드 및 펩티드 유사체
RU2561582C2 (ru) * 2010-11-19 2015-08-27 Российская Федерация в лице Министерства промышленности и торговли Российской Федерации Инъекционная лекарственная форма олигопептидного препарата для лечения рассеянного склероза и способ ее получения
JP5971729B2 (ja) * 2011-02-23 2016-08-17 北海道公立大学法人 札幌医科大学 疼痛を治療、改善、または予防するための組成物
RU2669692C1 (ru) * 2017-08-14 2018-10-15 Павел Андреевич Канаев Способ получения комплекса биологически активных пептидов обладающих нейротропной активностью
CN114642720A (zh) 2018-03-23 2022-06-21 百祥制药公司 皂化蛋白c药物组合物和治疗癌症的方法
KR20200138743A (ko) 2018-03-29 2020-12-10 레터럴 아이피 피티와이 리미티드 시클릭 펩티드 및 이의 용도
WO2022150666A1 (en) * 2021-01-09 2022-07-14 Bexion Pharmaceuticals Inc. Methods of reducing neuropathy and neuropathic symptoms and treating cancer

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3750197D1 (de) 1986-04-22 1994-08-18 Salk Inst For Biological Studi Antagonisten des Fibroblasten-Wachstumsfaktors.
DD298412A5 (de) * 1989-04-28 1992-02-20 ������@���Kk�� Verfahren zur herstellung von polypeptiden, die geeignet sind als antagonisten exzitatorischer aminosaeure-neurotransmitter und/oder blocker der calciumkanaele
US5169764A (en) * 1990-08-08 1992-12-08 Regeneron Pharmaceuticals, Inc. Multitrophic and multifunctional chimeric neurotrophic factors, and nucleic acids and plasmids encoding the chimeras
US5187151A (en) * 1991-02-12 1993-02-16 Genentech, Inc. Use of binding protein with igf-i as an anabolic growth promoting agent
RU2007417C1 (ru) * 1991-06-21 1994-02-15 Российский государственный медицинский университет Способ получения плацентарного протеина
US5470582A (en) 1992-02-07 1995-11-28 Syntex (U.S.A.) Inc. Controlled delivery of pharmaceuticals from preformed porous polymeric microparticles
US5534495A (en) * 1993-05-25 1996-07-09 Advanced Peptides And Biotechnology Sciences Treatment of non-HIV neuropathic pain syndromes
US5571787A (en) 1993-07-30 1996-11-05 Myelos Corporation Prosaposin as a neurotrophic factor
US5700909A (en) * 1993-07-30 1997-12-23 The Regents Of The University Of California Prosaposin and cytokine-derived peptides
CA2176708A1 (en) * 1993-11-15 1995-05-26 Christopher A. Maack Method of treating neurological disorders
CA2282827A1 (en) * 1997-03-05 1998-09-11 The Regents Of The University Of California Method of alleviating neuropathic pain
AU7795698A (en) * 1997-03-24 1998-10-20 Myelos Corporation Synthetic saposin c-derived neurotrophic peptides

Also Published As

Publication number Publication date
US6271196B1 (en) 2001-08-07
KR19990087686A (ko) 1999-12-27
EP0929569B1 (en) 2006-09-20
NZ331757A (en) 1999-10-28
AU734566B2 (en) 2001-06-14
DE69736712T2 (de) 2007-09-13
AU2328697A (en) 1997-09-22
CA2248139A1 (en) 1997-09-12
WO1997032895A1 (en) 1997-09-12
CA2248139C (en) 2004-05-18
RU2266129C2 (ru) 2005-12-20
ATE340187T1 (de) 2006-10-15
NO984093D0 (no) 1998-09-04
IL126082A0 (en) 1999-05-09
CZ283998A3 (cs) 1999-05-12
SK122898A3 (en) 2000-02-14
KR100507715B1 (ko) 2006-05-26
EP0929569A4 (en) 2000-08-23
PL187917B1 (pl) 2004-11-30
CZ297384B6 (cs) 2006-11-15
JP4138006B2 (ja) 2008-08-20
PL328701A1 (en) 1999-02-15
EP0929569A1 (en) 1999-07-21
US6268347B1 (en) 2001-07-31
RU2223969C2 (ru) 2004-02-20
JP2000506853A (ja) 2000-06-06
DE69736712D1 (de) 2006-11-02
RU2003131695A (ru) 2005-04-10

Similar Documents

Publication Publication Date Title
NO984093D0 (no) FremgangsmÕter for lindring av neuropatisk smerte ved bruk av prosaposin-abledete peptider
AU7321598A (en) Use of cholinesterase inhibitors to treat disorders of attention
DK0867178T3 (da) Non-allosteriske GABA A agonister til behandling af søvnforstyrrelser
AU9021298A (en) Agmatine as a treatment for neuropathic pain
EA200000239A1 (ru) Стимуляторы секреции гормона роста
EP0813544A4 (cg-RX-API-DMAC10.html)
EP1049479A4 (en) ANALGESIC OBTAINED FROM SNAKE VENOM
EA199800866A1 (ru) Способ снятия боли
IL143516A0 (en) COMPOUNDS AND METHODS FOR MODULATING ACTIVATION OF NF-k-B
EA199800864A1 (ru) Способ лечения при боли, вызванной мигренью
AU3308099A (en) Method for the treatment of pain, including chronic and female specific pain
WO1999065475A3 (en) Combination of phentolamine and apomorphine for the treatment of human sexual function and dysfunction
NO982582L (no) Fremgangsmaate for behandling av smerte
NO984189L (no) FremgangsmÕte for behandling av bipolar forstyrrelse
ATE270113T1 (de) Zusammenstellungen zur verbesserten wundheilung
EP1083914A4 (en) TREATING ARTHRITIS AND OTHER SIMILAR DISORDERS
ATE306278T1 (de) Behandlung von knochenleiden mit adrenomedullin
IL126158A0 (en) Method for treating substance abuse
AU5434899A (en) Cancer treatment
NO984198D0 (no) Fremgangsmåte for behandling av aggresjon
NO984190L (no) FremgangsmÕte for behandling av insomnia
AU4390597A (en) Combination therapy for treatment of arthritic diseases
NO985325L (no) Anvendelse av substituert azaspiran ved behandling av astma
NO965029D0 (no) Cellulære faktorer som regulerer ekspresjon av gener som koder for proteiner involvert i kolesterolhomeostase
UA43389C2 (uk) Спосіб зниження рівнів кальцію у сироватці

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application